IMR Press / EJGO / Special Issues / 1606386705999

Human Papillomavirus and Gynaecological Oncology

Section: Cervical Cancer
Submission deadline: 30 September 2021
Special Issue Editors
Julio Cesar Teixeira, MD
Director of Oncology Division, Women’s Hospital, University of Campinas, Campinas, Sao Paulo State, Brazil
Interests: HPV; Lesões Precursora; Ginecologia Oncológica; Vacinas
Special Issue Information

Dear Colleagues,

The European Journal of Gynaecological Oncology planned a special issue with focuses on gynaecological cancer related to Papillomavirus (HPV) infection.

These neoplasms are an important burden of disease and predominate in specific populations, either by age, immunological condition or access to health care. The main gynecological cancer site is the uterine cervix, followed by the vulva and vagina. In general, second cancer with the highest proportion of HPV association is the cancer of the canal anal. Vaccination against the main high-risk oncogenic types is available since 2007 and has an irregular spread, with few sites reaching the necessary coverage of the primary target population, that is preadolescents or those before sexual initiation. Countries that have achieved success with high vaccine coverage in a sustained manner have already recorded a significant drop in cervical precursor lesions and now, significantly fewer cervical cancer cases.

Due to the existence of the tools to eliminate these cancers and the inequity of access, WHO is coordinating efforts in a challenging global campaign to expand vaccination coverage, screening for cervical precursor lesions, and treatment access, to achieve a significant impact by 2030. Besides, screening should progressively shift to DNA-HPV testing, crucial for the previously vaccinated population that is reaching the target age of existing programs.

Therefore, this special issue is planned for May 2021. The theme will be ‘Human Papillomavirus and Gynaecological Oncology’ and I have included the official call for papers below. If you would be able to contribute, we would be delighted to hear from you. 

Julio Cesar Teixeira

Guest Editor

HPV Vaccine
HPV Test
Preneoplastic Lesion
Cervical Cancer
Vaginal Cancerl Vulvar Cancerl Treatment
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top